CoChat

Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Atomoxetine (Strattera) is a selective noradrenaline (norepinephrine) reuptake inhibitor that is not classified as a stimulant, and is indicated for use in patients with attention-deficit hyperactivity disorder (ADHD). Atomoxetine is effective and generally well tolerated. It is significantly more effective than placebo and standard current therapy and does not differ significantly from, or is noninferior to, immediate-release methylphenidate; however, it is significantly less effective than the extended-release methylphenidate formulation OROS methylphenidate (hereafter referred to as osmotically released methylphenidate) and extended-release mixed amfetamine salts. Atomoxetine can be administered either as a single daily dose or split into two evenly divided doses, has a negligible risk of abuse or misuse and is not a controlled substance in the US. Atomoxetine is particularly useful for patients at risk of substance abuse, as well as those who have co-morbid anxiety or tics, or who do not wish to take a controlled substance. Thus, atomoxetine is a useful option in the treatment of ADHD in children and adolescents.

Overview

Integrity signals

Registry

Crossref · 10.2165/11203670-000000000-00000

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Cited by

See all 32

Metadata

Authors
Garnock-Jones, K. P., & Keating, G. M.
Affiliations
Wolters Kluwer Health (NZ)
Corresponding author
Garnock-Jones, Karly P.
Venue
CNS Drugs
Published
2010-01
Volume
24
Issue
1
Pages
85-88
ISSN
1172-7047 (ISSN-L)
OpenAlex
W1965390021
Cited by
32
References
49
Citations by year
2020: 3 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 5 · 2015: 1 · 2014: 3 · 2013: 5 · 2012: 4
FWCI
2.06
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
atomoxetine, attention deficit hyperactivity disorder, norepinephrine reuptake inhibitors, methylphenidate, extended-release methylphenidate, amphetamine salts, drug efficacy, drug tolerability, abuse risk, children and adolescents
MeSH terms
Atomoxetine Hydrochloride, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Clinical Trials as Topic, Humans, Propylamines, Economics, Pharmaceutical, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†. https://app.cochat.ai/papers/10.2165/11203670-000000000-00000
The paper
Garnock-Jones, K. P., & Keating, G. M. (2010). Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†. CNS Drugs. https://doi.org/10.2165/11203670-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.